Prof. Nicholas Francis (England)
CRP Point of Care testing to reduce antibiotic prescribing in acutely exacerbated COPD patients
Prof. Ivan Gentile (Italy)
Severity assessment and outcome prediction in the COVID-19 patients
Carl Llor (Spain)
The emergence of multi-resistance associated with the overuse of antibiotics during COVID-19 pandemic
Dag Berild (Norway)
Antimicrobial stewardship in the time of COVID-19 is vital — AMR still persists and could be height
Dr. Aggy York (England)
Panel Discussion: CRP and Point of Care testing — knowledge sharing from across Europe
Register its Free
Join of panel of experts from across Europe for this compelling webinar presenting a view from the front line in Europe.
The webinar will highlight the importance now more that ever of Antibiotic Stewardship Programs (ASPs) in the context of the global pandemic and how antibiotics should be used only when necessary in order to curb the rise of AMR. 90 % of Respiratory Tract Infections (RTIs) are viral yet RTI's are one of the most common reasons for unnecessary antibiotic prescribing, yet antibiotics have no clinical benefit to the patient for RTIs.  
The webinar will also showcase the findings of the PACE study which recommended that CRP Point of Care testing can guide antibiotic therapy in acutely exacerbated COPD. 
- Despite the viral origin of COVID-19, a standard reflex by physicians is to start treatment with antibiotics since cough, fever and radiologic infiltrates are hallmarks of bacterial community-acquired pneumonia, which requires antibiotic treatment. 
- CRP represents a useful marker of severity in patients with COVID-19, as it correlates with prognosis and need for mechanical ventilation.
- CRP may reflect disease severity and may be an independent predictor of adverse outcomes in COVID-19 patients.     
- The detection of C-reactive protein (CRP) is of certain value to distinguish whether there is a bacterial infection in the lung. 
- Antibiotics should be reserved for the patients with the most severe presentations. 
- Avoid blind or inappropriate use of antibacterial drugs, especially the combination of broad-spectrum antibacterial drugs
- ↑ Bode B, Garrett V, Messler J et. al. J Diabetes Sci Technol. 2020; 9 May. Online ahead of print.
- ↑ Palmieri L, Andrianou X, Barbariol P et al. COVID-19 Surveillance Group. Report based on available data on April 20th, 2020. EpiCentro. Accessed 5 June, 2020.
- ↑ Chen Y, Yang D, Cheng B. Diabetes Care. 2020; May 14. Online ahead of print.
- ↑ Guan W, Ni Z, Hu Y et. al. New Engl J Med. 2020;382:1708-20.
- ↑ Zhu L, She Z-G, Chen X et al. Cell Metabolism. 2020 ; 31 :1068-1077.
- ↑ Tan C et al. ORCID iD: 0000-0002-2522-4524.
- ↑ Wang L. Médecine et maladies infectieuses 2020.
- ↑ Butler CC et al. C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations. The New England Journal of Medicine 2019; 381 (2): 111-120.
- ↑ CDC COVID-19 Response Team. Morbidity and Mortality Weekly Report April 3, 2020; 69(13):382-386.
- ↑ Richardson S. Hirsch JS, Narasimhan M et. al. JAMA. 2020; 323(20):2052-2059.
- ↑ Jin YH et al. Position article and guideline. Military Medical Research (2020) 7:4;
- ↑ Huttner B et al. Clinical Microbiology and Infection 2020;